Abstract
Convincing evidence that early visual recognition memory (VRM) is a potential index of later cognitive function is rapidly accumulating. A standardized test of infant VRM to be used as a screening device to identify those infants at high risk for later cognitive delays appears to be a logical next step. The Fagan Test of Infant Intelligence (FTII) is the first such screening measure that has been commercially marketed. The FTII is well grounded empirically and as a research tool is well thought out and systematized. However, when considered as a standardized clinical test some major deficits emerge, including inadequate statistical documentation, a nominal standardization sample, and insufficient reliability and validity information. The FTII is critiqued, and methodological, statistical, and theoretical issues pertaining to this test and to dissemination of such instruments are discussed.